Gilead, HIV and lenacapavir

Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year | After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate,
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is departing after 14 years.
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Barchart on MSN19h
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
News-Medical.Net on MSN2d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The Financial Express19h
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Gilead Sciences's Options: A Look at What the Big Money is Thinking
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Bernstein Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back ...
BioSpace2d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...